摘要
目的评价阿立哌唑和氯丙嗪治疗双相Ⅰ型障碍躁狂发作的疗效及安全性。方法采用随机双盲对照研究方法,对86例双相Ⅰ型障碍躁狂发作患者分别进行阿立哌唑(阿立哌唑组)和氯丙嗪(氯丙嗪组)治疗,其中阿立哌唑组43例,平均剂量(18.04±3.52)mg/d;氯丙嗪组43例,平均剂量(369.81±82.43)mg/d;观察疗程均为4周。以Young躁狂评定量表作为主要疗效评价指标。结果阿立哌唑组患者的有效率为84%,氯丙嗪组的有效率为78%。PP人群统计学分析,阿立哌唑治疗急性躁狂的疗效不劣于氯丙嗪。阿立哌唑组的锥体外系不良反应的发生率(19%)明显低于氯丙嗪组(37%),差异有统计学意义(P<0.05)。结论阿立哌唑治疗双相Ⅰ型障碍躁狂发作的疗效与氯丙嗪相当,锥体外系等不良反应少于氯丙嗪。
Objective To evaluate the efficacy and safety of aripiprazole and chlorpromazine in treating patients with bipolar Ⅰ disorder acute manic episodes. Methods A randomized, double-blind, controlled clinical trial was conducted. All 86 patients received 4 weeks treatment with either aripiprazole （n=43,averaged dosage of 18.04±3.52）or chlorpromazine （n=43,369.81±82.43mg/d）. The main efficacy measure was the change in total score of the Young Mania Rating Scale. Results The clinical response rates were 84% in aripiprazole group and 78% in chlorpromazine group. There were significantly higher rates of extrapyramidal symptoms in chlorpromazine group （37%）than that in aripiprazole group （19%）. Conclusion The results show that aripiprazole has similar therapeutic effect to chlorpromazine in the treatment of acute manic episodes, but aripiprazole has better tolerability.
出处
《精神医学杂志》
2007年第3期161-163,共3页
Journal of Psychiatry
